Mechanistic Studies on the Inactivation of Plasminogen Activator Inhibitor (PAI-1) by PAI-749, a Small Molecule PAI-1 Antagonist

被引：0
|
作者：
Gardell, S. [1 ]
Antrilli, T. [1 ]
Elokdah, H. [1 ]
Krueger, J. [1 ]
Mayer, S. [1 ]
Orcutt, S. [1 ]
Vlasuk, G. [1 ]
Crandall, D. [1 ]
机构：
[1] Wyeth Res, Collegeville, PA USA
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2006年 / 4卷
关键词：
PAI-1; antagonist; profibrinolytic;
D O I：
10.1111/j.1538-7836.2006.00225.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
225
引用
收藏
页码：169 / 169
页数：1
相关论文
共 50 条
  • [1] Mechanistic studies on the inactivation of plasminogen activator inhibitor 1 (PAI-1) by the small molecule PAI-1 antagonist PAI-749
    Gardell, SJ
    Antrilli, TM
    Elokdah, H
    Krueger, JA
    Mayer, S
    Orcutt, SJ
    Vlasuk, GP
    Crandall, DL
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2006, 26 (05) : E104 - E104
  • [2] Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis
    Lucking, A. J.
    Visvanathan, A.
    Philippou, H.
    Fraser, S.
    Grant, P. J.
    Connolly, T. M.
    Gardell, S. J.
    Feuerstein, G. Z.
    Fox, K. A. A.
    Booth, N. A.
    Newby, D. E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2010, 8 (06) : 1333 - 1339
  • [3] Neutralization of plasminogen activator inhibitor I (PAI-1) by the synthetic antagonist PAI-749 via a dual mechanism of action
    Gardell, Stephen J.
    Krueger, Julie A.
    Antrilli, Thomas A.
    Elokdah, Hassan
    Mayer, Scott
    Orcutt, Steven J.
    Crandall, David L.
    Vlasuk, George P.
    MOLECULAR PHARMACOLOGY, 2007, 72 (04) : 897 - 906
  • [4] Plasminogen activator inhibitor type 1 (PAI-1) level and activity at patients with PAI-1 polymorphism
    Shelest, A.
    Matveeva, M. A.
    Popova, L., V
    Patrushev, L., I
    Shuganov, E. G.
    Gneusheva, T. Y.
    Bokarev, I. N.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 1173 - 1173
  • [5] Effect of troglitazone on plasminogen activator inhibitor on (PAI-1)
    Fonseca, V
    Reynolds, T
    Hemphill, D
    Randolph, C
    Valiquett, T
    Graveline, J
    Fink, L
    DIABETOLOGIA, 1997, 40 : 1616 - 1616
  • [6] DAYTIME FLUCTUATIONS OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1) IN POPULATIONS WITH HIGH PAI-1 LEVELS
    JUHANVAGUE, I
    ALESSI, MC
    RACCAH, D
    AILLAUD, MF
    BILLEREY, M
    ANSALDI, J
    PHILIPJOET, C
    VAGUE, P
    THROMBOSIS AND HAEMOSTASIS, 1992, 67 (01) : 76 - 82
  • [7] Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin - Characterization of different PAI-1 mutants
    De Prada, NA
    Schroeck, F
    Sinner, EK
    Muehlenweg, B
    Twellmeyer, J
    Sperl, S
    Wilhelm, OG
    Schmitt, M
    Magdolen, V
    EUROPEAN JOURNAL OF BIOCHEMISTRY, 2002, 269 (01): : 184 - 192
  • [8] Efficacy of PAI-749, an orally active PAI-1 inhibitor, in dog and rat models of arterial and venous thrombosis
    Hennan, J.
    Morgan, G.
    Swillo, R.
    Ji, A.
    Guan, L.
    Crandall, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 : 167 - 167
  • [9] Inactivation of plasminogen activator inhibitor-1 (PAI-1) by XR5118
    Faint, R
    Charlton, P
    Templeton, D
    Bent, F
    Folkes, A
    Mackie, I
    Machin, S
    Bevan, P
    BLOOD, 1996, 88 (10) : 1121 - 1121
  • [10] Do plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator PAI-1 complexes (tPA-PAI-1) Predict complications in type 1 diabetes (TID)?
    Bosnyak, Z
    Forrest, KYZ
    Maser, RE
    Orchard, TJ
    DIABETES, 2001, 50 : A209 - A209
12345